Penpulimab vs Toripalimab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Penpulimab
Marketed by Akeso and partners
NCT03866993 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.
Reported efficacy
Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)
Result source: NCT03866993
Toripalimab
Marketed by Coherus BioSciences, Inc. and partners
NCT03856411 · Phase 3 · completed
This randomized, quadruple-blind, placebo-controlled trial of 465 patients met its primary endpoint: median progression-free survival was 8.4 months with toripalimab plus chemotherapy versus 5.6 months with placebo plus chemotherapy, a highly statistically significant improvement.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06426511 (registry estimate)
Reported efficacy
MPR rate in stage III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage III population evaluated by investigators (up to 3 years); MPR rate in stage II-III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage II-III population evaluated by investigators (up to 3 years): Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met. (met)
Result source: NCT04158440
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Penpulimab | Toripalimab |
|---|---|---|
| PFS, median | 8.6 vs 4.2a+4.4 vs placeboNCT03866993 | 8.4 vs 5.6a+2.8 vs placeboNCT03856411 |
| OS, median | —Not posted · NCT03866993 | —Not posted · NCT03856411 |
| ORR | —Not posted · NCT03866993 | —Not posted · NCT03856411 |
| Duration of response, median | —Not posted · NCT03866993 | —Not posted · NCT03856411 |
PFS, median
- Penpulimab
- 8.6 vs 4.2a+4.4 vs placeboNCT03866993
- Toripalimab
- 8.4 vs 5.6a+2.8 vs placeboNCT03856411
OS, median
- Penpulimab
- —Not posted · NCT03866993
- Toripalimab
- —Not posted · NCT03856411
ORR
- Penpulimab
- —Not posted · NCT03866993
- Toripalimab
- —Not posted · NCT03856411
Duration of response, median
- Penpulimab
- —Not posted · NCT03866993
- Toripalimab
- —Not posted · NCT03856411
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Nasopharyngeal Carcinoma
Shared mechanism: PD-1 · full Nasopharyngeal Carcinoma pipeline
Penpulimab
Marketed by Akeso and partners
NCT04974398 · Phase 3 · active, not recruiting
Patients were randomly assigned to penpulimab or a matching placebo with patients, doctors and assessors all blinded, and the trial met its primary endpoint, progression-free survival judged by blinded central review. A power calculation was reported, and 291 patients were randomized against a planned 278.
No aligned efficacy figure on record for this race.
Toripalimab
Marketed by Coherus BioSciences, Inc. and partners
NCT03581786 · Phase 3 · completed
JUPITER-02 was a randomized, double-blind, placebo-controlled Phase 3 in 289 patients with recurrent or metastatic nasopharyngeal carcinoma. Its primary endpoint, independently reviewed progression-free survival, is a clinical outcome and was met (HR 0.52). Figures are from the FDA label; the sources read give no power calculation, so the grade is moderate.
Next expected readout: December 2026 · NCT06323239 (registry estimate)
Reported efficacy
IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 (up to 2 years): Primary endpoint, IRC-assessed PFS: median 11.7 vs 8.0 months, hazard ratio 0.52 (95% CI 0.36 to 0.74), toripalimab plus gemcitabine-cisplatin vs placebo plus gemcitabine-cisplatin (LOQTORZI label, JUPITER-02). (met)
Result source: NCT03581786
Results for Nasopharyngeal Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Penpulimab: no structured comparison results are available for Nasopharyngeal Carcinoma.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Toripalimab's landscape